Loading
A phase 1 trial of DAN-222 run by Dantari, Inc., completed.
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer is a phase 1 interventional study registered as NCT05261269 by Dantari, Inc., with 30 participants enrolled, started 2022-02-02. Conditions recorded: HER2-negative Metastatic Breast Cancer. Interventions recorded: DAN-222 and Niraparib.
Shares Dantari and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/